Navigation Links
BELLUS Health reports results for first quarter of fiscal 2009
Date:5/6/2009

LAVAL, QC, May 6 /PRNewswire-FirstCall/ - BELLUS Health Inc. ("BELLUS Health" or the "Company") (TSX: BLU) reported results for the first quarter ended March 31, 2009. The Company reported a net loss of $9,907,000 ($0.20 per share) for the quarter, compared to $13,042,000 ($0.27 per share) for the same period the previous year. The decrease in the net loss is mainly due to a reduction in research and development (R&D) expenses, before research tax credits and grants, which amounted to $3,610,000 for the current quarter, compared to $8,780,000 for the same period the previous year. The decrease is mainly attributable to a reduction in the research and development of tramiprosate (ALZHEMED(TM); homotaurine) for the treatment of Alzheimer's disease following the Company's decision in November 2007 to terminate the tramiprosate (ALZHEMED(TM)) pharmaceutical drug development program. The Company is also developing NC-503 (eprodisate) for the treatment of Type II diabetes and certain features of metabolic syndrome.

As at March 31, 2009, the Company had available cash, cash equivalents and marketable securities of $3,187,000, compared to $10,595,000 at December 31, 2008. The decrease is primarily due to funds used in operating activities.

On April 16, after the end of the first quarter of 2009, the Company announced the completion of the first tranche of its previously announced $20.5 million CAD convertible notes (see Liquidity and capital resources section for further details). BELLUS Health received gross proceeds of $10 million CAD for the issuance of new convertible notes. A second tranche of $10.5 million CAD is expected to be funded by June 2009. In March 2009, the Company announced a reduction in the workforce and other related measures which are expected to result in annual savings of approximately $3.5 million CAD, and the restructuring of the lease of the Company's main premises and the 2006 and 2007 convertible notes, which are expect
'/>"/>

SOURCE BELLUS HEALTH INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. BELLUS announces Chief Financial Officer to depart effective May 22, 2009
2. BELLUS Health inc. announces completion of first tranche of financing
3. BELLUS Health reports results for the fourth quarter of 2008
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc.
5. BELLUS Health announces formal notice to voluntarily delist from NASDAQ
6. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
7. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
8. BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
9. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
10. BELLUS Health provides update on activities
11. BELLUS Health announces closing of Innodia acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 "The second ... it’s uncomfortable and painful to wear shoes," said an inventor ... special sock that prevents this from happening. , He then ... effective way to prevent the second and big toes from ... endurance while wearing shoes. Ergonomic and easy to use, it's ...
(Date:7/12/2014)... 2014 As DePuy Pinnacle hip lawsuits ... courts, Bernstein Liebhard LLP notes the publication of a ... the failure of metal-on-metal hip replacements. The research, which ... of Bone & Joint Surgery, looked at 597 ... prostheses at least twelve months earlier. The blood metal ...
(Date:7/12/2014)... “Critical Care Therapeutics in Major Developed ... PCCs and Recombinant Products to Drive Market,” which ... in the US, UK, France, Germany, Italy, Spain, ... of market size for 2013, along with market ... that are being treated using the five major ...
(Date:7/12/2014)... Arab Emirates (PRWEB) July 12, 2014 ... Los Angeles basketball legend is heading to the UAE. ... and six-time champion will be in the UAE from ... Fitness Weekend in support of diabetes awareness. The event ... award-winning entertainment marketing and event management company based in ...
(Date:7/12/2014)... Seattle, Wa (PRWEB) July 12, 2014 ... by Doctors Sen and Samantha Pearson, a couple boasting ... chose to launch Restore My Vision Today as a ... that many ophthalmologists have become in their respective ... makes readers privy to a “secret” trove of pertinent ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3
... 2011) -Texas Children,s Hospital in Houston announces that ... earned a National Science Foundation Early Career Development (CAREER) ... congenital heart disease, heart defects, and the development of ... amniotic fluid. The award comes with new funding of ...
... brain function variations between the left and right sides ... weight of the placenta. The finding could shed new ... later life. The research, conducted at the University ... Epidemiology Unit at Southampton General Hospital, reveals that children ...
... Spanish . Between 5 % and 10 % of ... father or mother a mutation in a gene that is susceptible to ... of the genes to be monitored. It is estimated that 30 % ... these two genes (which suggests, at the same time, that there are ...
... the University of the Basque Country (UPV/EHU) has carried ... between the sexes and generations in terms of forgiveness. ... while women are better at forgiving than men. ... it shows us what reasons people have for forgiving ...
... both type 1 diabetes and CKD have an increased ... with type 1 diabetes and overt nephropathy develop End-Stage ... The competing risks of death and ESRD may confound ... Now, the researchers at the University of Helsinki, University ...
... Reporter , THURSDAY, Feb. 17 (HealthDay News) -- Cyclists ... street traffic have fewer accidents compared to bikers pedalling ... found that there is a 28 percent lower injury ... in parallel and comparable roads," noted study lead author ...
Cached Medicine News:Health News:Tissue engineering methods earn funding to heal little hearts 2Health News:Brain function linked to birth size in groundbreaking new study 2Health News:Ph.D. thesis on 2 genes involved in hereditary breast and ovary cancer cases 2Health News:Women are better at forgiving 2Health News:Competing risks analysis highlights new targets in preventing ESRD and death of diabetics 2Health News:Separate Bikes-Only Lanes in Cities Cut Injury Rate: Study 2Health News:Separate Bikes-Only Lanes in Cities Cut Injury Rate: Study 3
(Date:7/10/2014)... July 11, 2014  Major advances in radiation ... are being highlighted in a three-day Oncology Summit ... from 10-12 July, 2014.  Renowned national and international cancer experts ... practices and exchange knowledge on modern technologies making ... efficient. The Summit will address ...
(Date:7/10/2014)... 10, 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... and analog IC solutions, today announced that it will ... 2014, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern ... fiscal 2014 third quarter ended June 30, 2014. ... 1-888-556-4997 before 6:50 a.m. Pacific time on July 24, ...
(Date:7/10/2014)... July 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... it has completed the sale to Galderma of all ... or held by Valeant for $1.4 billion in cash, ... which recently completed its acquisition of Galderma. ... our products to a company that is firmly committed ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
Iems Incubator/Shaker expansion module for 2 module incubator/shaker. high performance microplate incubator and orbital shaker. It's superior temperature control and efficient orbital shaking reduce ...
... are designed to give reliable performance for all ... on/off button, power supply socket and fuse holder ... unit. The speed knob is located on the ... from a minimum 950 rpm to a maximum ...
The BD LSR II can be configured with up to four fixed alignment lasers and the ability to detect up to 15 colors, utilizing a revolutionary optical design. The BD LSR II can be configured with a 488 ...
... especially suited for cell analysis and ... allows to analyze scatter signals in ... channels. Data acquisition, analysis, and real-time ... PC employing Partec DPAC software, built-in ...
Medicine Products: